Abstract
Bioengineering of bladder tissue, particularly for those patients who have advanced bladder disease, requires a source of urothelium that is healthy, capable of significant proliferation in vitro and immunologically tolerated upon transplant. As pluripotent stem cells have the potential to fulfill such criteria, they provide a critical cell source from which urothelium might be derived in vitro and used clinically. Herein, we describe the in vitro differentiation of urothelium from the H9 human embryonic stem cell (hESC) line through the definitive endoderm (DE) phase via selective culture techniques. The protocol can be used to derive urothelium from other hESCs or human-induced pluripotent stem cells.
| Original language | English (US) |
|---|---|
| Title of host publication | Methods in Molecular Biology |
| Publisher | Humana Press Inc. |
| Pages | 137-144 |
| Number of pages | 8 |
| Volume | 1655 |
| DOIs | |
| State | Published - 2018 |
Publication series
| Name | Methods in Molecular Biology |
|---|---|
| Volume | 1655 |
| ISSN (Print) | 1064-3745 |
Fingerprint
Keywords
- Activin A
- Bladder bioengineering
- Definitive endoderm
- Human embryonic stem cells
- Induced pluripotent stem cells
- Uroplakins
- Urothelium
ASJC Scopus subject areas
- Molecular Biology
- Genetics
Cite this
In vitro differentiation and propagation of urothelium from pluripotent stem cell lines. / Osborn, Stephanie L.; Kurzrock, Eric A.
Methods in Molecular Biology. Vol. 1655 Humana Press Inc., 2018. p. 137-144 (Methods in Molecular Biology; Vol. 1655).Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - In vitro differentiation and propagation of urothelium from pluripotent stem cell lines
AU - Osborn, Stephanie L.
AU - Kurzrock, Eric A
PY - 2018
Y1 - 2018
N2 - Bioengineering of bladder tissue, particularly for those patients who have advanced bladder disease, requires a source of urothelium that is healthy, capable of significant proliferation in vitro and immunologically tolerated upon transplant. As pluripotent stem cells have the potential to fulfill such criteria, they provide a critical cell source from which urothelium might be derived in vitro and used clinically. Herein, we describe the in vitro differentiation of urothelium from the H9 human embryonic stem cell (hESC) line through the definitive endoderm (DE) phase via selective culture techniques. The protocol can be used to derive urothelium from other hESCs or human-induced pluripotent stem cells.
AB - Bioengineering of bladder tissue, particularly for those patients who have advanced bladder disease, requires a source of urothelium that is healthy, capable of significant proliferation in vitro and immunologically tolerated upon transplant. As pluripotent stem cells have the potential to fulfill such criteria, they provide a critical cell source from which urothelium might be derived in vitro and used clinically. Herein, we describe the in vitro differentiation of urothelium from the H9 human embryonic stem cell (hESC) line through the definitive endoderm (DE) phase via selective culture techniques. The protocol can be used to derive urothelium from other hESCs or human-induced pluripotent stem cells.
KW - Activin A
KW - Bladder bioengineering
KW - Definitive endoderm
KW - Human embryonic stem cells
KW - Induced pluripotent stem cells
KW - Uroplakins
KW - Urothelium
UR - http://www.scopus.com/inward/record.url?scp=85029354023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029354023&partnerID=8YFLogxK
U2 - 10.1007/978-1-4939-7234-0_11
DO - 10.1007/978-1-4939-7234-0_11
M3 - Chapter
C2 - 28889383
AN - SCOPUS:85029354023
VL - 1655
T3 - Methods in Molecular Biology
SP - 137
EP - 144
BT - Methods in Molecular Biology
PB - Humana Press Inc.
ER -